EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer‐Specific Polygenic Scores

Brendan Prassas, Zhuqing Shi, Huy Tran, Jun Wei, Chi-Hsiung Wang, Andrew S Rifkin iD, Annabelle Ashworth, S Lilly Zheng, Ashley J Mulford, Alan R Sanders, Catherine E Pesce, Brian T Helfand und 5 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70990 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Brendan Prassas und 16 weiteren Autor:innen. Beteiligte Einrichtung: Program for Genomic Translational Research, NorthShore University HealthSystem (Endeavor Health), Evanston, Illinois, USA. Hauptthemen laut MEDLINE: Penetrance, BRCA2 Protein, Neoplasms, Multifactorial Inheritance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

BRCA2 is a causal gene for hereditary breast and ovarian cancer (HBOC) syndrome. However, its association with other cancers and interplay with polygenic scores (PGS) remains unclear.

Methods

An observational cohort study for the diagnosis of various cancers in the UK Biobank (UKB, N = 453,541) were recruited at ages of 40–69 years Association of germline pathogenic variants (PVs) in BRCA2 and published cancer‐specific PGS with cancer risk was tested using Cox proportional hazards model.

Results

The median age and interquartile range (IQR) of participants at the analysis was 58.34 (50.60–63.74) years. Carriers of BRCA2 PVs ( N = 1629) had a significantly increased risk for four core HBOC‐associated cancers (breast, ovarian, pancreatic, and prostate) and six additional types of cancer (lung, oral, small intestine, larynx, liver, and mesothelioma), hazard ratio (HR) > 2.37, all p s < 0.001. For eight cancers where cancer‐specific PGS is available, each PGS was significantly associated with its respective cancer risk and independent of BRCA2 , HR > 1.25 for 1 unit increase in standard deviation, all p s < 0.001. For female breast and prostate cancer, a significant interaction between BRCA2 and PGS was found (HR < 0.83, p < 0.05); the effect of PGS on cancer risk was weaker in carriers than noncarriers. The probability of cancer by age 75 years (P 75 ) for these 10 cancers increased with higher PGS deciles in both carriers and noncarriers. For several cancers, the P 75 in carriers with the lowest PGS decile was lower than that of noncarriers with the highest PGS decile.

Conclusions

BRCA2 PVs increase risk beyond core HBOC cancers and their risks are modified by cancer‐specific PGS. These results suggest that genetic counseling of BRCA2 PV carriers may extend to cancers beyond core HBOC syndrome and incorporate cancer‐specific PGS in estimating their penetrance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PenetranceBRCA2 ProteinNeoplasmsMultifactorial InheritanceHereditary Breast and Ovarian Cancer SyndromeHumansMiddle AgedFemaleAgedMaleAdultGerm-Line MutationGenetic Predisposition to DiseaseHeterozygoteUnited Kingdom

Stichwörter der Autor:innen

BRCA2breast cancer (female and male)hereditary breast and ovarian cancer syndrome (HBOC)liver cancerlung canceroral cancerovarian cancerpancreatic cancerpolygenic scoreprostate cancer

Substanzen

BRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Program for Genomic Translational Research, NorthShore University HealthSystem (Endeavor Health), Evanston, Illinois, USA.
  • Genomic Health Initiative, NorthShore University HealthSystem (Endeavor Health), Evanston, Illinois, USA.
  • University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.
  • Department of Surgery, NorthShore University HealthSystem (Endeavor Health), Evanston, Illinois, USA.
  • Neaman Center for Personalized Medicine, NorthShore University HealthSystem (Endeavor Health), Evanston, Illinois, USA.
  • Translational Genomics Research Institute, Part of City of Hope, Phoenix, Arizona, USA.

ORCID-Profile: Andrew S Rifkin, Allison DePersia, Jianfeng Xu

Zitieren

APA

Prassas, B., Shi, Z., Tran, H., Wei, J., Wang, C. H., Rifkin, A. S., Ashworth, A., Zheng, S. L., Mulford, A. J., Sanders, A. R., Pesce, C. E., Helfand, B. T., Dunnenberger, H. M., Duggan, D., Hulick, P. J., DePersia, A., & Xu, J. (2025). Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer‐Specific Polygenic Scores. Cancer Medicine. https://doi.org/10.1002/cam4.70990

Vancouver

Prassas B, Shi Z, Tran H, Wei J, Wang CH, Rifkin AS, et al. Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer‐Specific Polygenic Scores. Cancer Medicine. 2025. doi:10.1002/cam4.70990

BibTeX
@article{Prassas2025,
  author = {Prassas, Brendan and Shi, Zhuqing and Tran, Huy and Wei, Jun and Wang, Chi-Hsiung and Rifkin, Andrew S and Ashworth, Annabelle and Zheng, S Lilly and Mulford, Ashley J and Sanders, Alan R and Pesce, Catherine E and Helfand, Brian T and Dunnenberger, Henry M and Duggan, David and Hulick, Peter J and DePersia, Allison and Xu, Jianfeng},
  title = {Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer‐Specific Polygenic Scores},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70990}
}
Kostenlos starten →